Caractérisation de la modulation de l’activité du récepteur nucléaire orphelin NUR77 (NR4A1) par ses modifications post-traductionnelles et son interactome
NUR77 is an orphan nuclear receptor (NR) involved in the regulation of multiple cell biology processes including cell death, in particular in Parkinson's disease (PD), which results of the loss of dopaminergic neurons, and in breast cancer (BC), which is caused by the proliferation of mammary epithelial cells. NUR77 is involved in triggering and inhibiting cell death and its activity is believed to be independent of a ligand binding. We hypothesized that the regulation of NUR77 activity does not occur through a ligand, but through the influence of its post-translational modifications (PTMs) and its interaction partners. The general objective of this PhD project was to characterize the PTMs and the interacting partners that modulate the activity of NUR77 in cultured cell models, to better understand its physiological roles, in particular in the regulation of cell death. The first objective of this thesis was to characterize the role of SUMOylation, a modification that regulates NR activity, in regulating NUR77 transcriptional activity in reporter assays in Human Embryonic Kidney (HEK293) cells. Overexpression of the E3 SUMO ligase PIASγ or/and the isoform 2 of SUMO, both important regulators in SUMOylation of the NUR77 homolog NURR1, produced a repressive effect on the transcriptional activity of NUR77. The effect of PIASγ on the activity of NUR77 was shown to be modulated by the Sentrin SUMO-specific protease 1 protein, which removes SUMO tags on target proteins. In addition, mutations of lysine residues in SUMO consensus sites in NUR77 (K102 and K577) had opposite effects on its transcriptional activity, suggesting different recruitment of coregulators of transcription in the regions. The combination of these results indicates that SUMOylation is an important PTM for the regulation of NUR77 activity and that PIASγ and SUMO2 proteins are important transcriptional coregulators of NUR77. The second objective of this thesis was to evaluate NUR77 interactome in HEK293 living cells to identify the interactors that can modulate its activity, using a biotin-labelling method for proximal proteins based on the APEX2 peroxidase combined with mass spectrometry. This approach identified 336 potential interactors of NUR77, some that are consistent with the literature. Coimmunoprecipitation and coimmunofluorescence assays carried out in HEK293 cells and in MCF-7 breast cancer cell line have shown that the regulator of apoptosis Apoptosis Inhibitor 5 vi (API5), interacted and colocalized with NUR77. By depriving cells of serum and decreasing API5 expression, increased protein levels and activity of NUR77 was observed, as well as a decrease in cell viability. These data support that API5 is a regulator of NUR77 in its involvement in signalling pathways associated with cell death and that this interaction could be a target for modulating apoptosis. More generally, they validate the APEX2 tool which can be used to identify novel NUR77 interactors. In conclusion, the work of this thesis resulted in the generation of tools to better understand the activity of NUR77 and revealed important coregulators in this activity. The continued characterization of these interactors may provide opportunities to target NUR77 as a regulator of cell death, particularly in PD and in breast cancer.
NUR77 SUMOylation PIASγ Interactome API5 APEX2 Parkinson Gene reporter assays Cell death Parkinson Disease Breast cancer